Nicolas Leupin
About Nicolas Leupin
Nicolas Leupin is the Chief Medical Officer at Novocure and a Lecturer in Tumor Biology at Universität Bern, with a diverse background in medical oncology, clinical development, and leadership.
Company
Nicolas Leupin is currently serving as the Chief Medical Officer at Novocure in Switzerland. Novocure is known for its innovative cancer therapies and strives to pioneer improvements in the fight against this disease. Leupin's role involves leading medical affairs, overseeing clinical trials, and contributing to the development of new therapeutic strategies.
Past Roles in the Medical Industry
Leupin has held significant roles in the medical industry. He worked at Molecular Partners AG as Chief Medical Officer from 2019 to 2024 in Zurich, Switzerland. Before this, he served as the Chief Medical Officer at argenx from 2016 to 2019 in Brussels, Belgium. His experience also includes a seven-year tenure in Clinical Development at Celgene from 2008 to 2015. Leupin's early career involved working at Hôpital du Valais, CHUV, Insel Gruppe, and SRO Langenthal in various clinical and research capacities.
Education and Expertise
Nicolas Leupin holds a diverse educational background. He earned his Doctor of Medicine (MD) from the University of Bern, followed by a Doctor of Philosophy (PhD) in Immunology, Oncology, and Hematology from UBFC - Université Bourgogne-Franche-Comté. He also holds an MBA in Negotiation and Conflict Management from Jones International University, and a Certificate in Leadership from IMD. Leupin has completed examinations from the Swiss Board and the European Society for Medical Oncology (ESMO) in Medical Oncology.
Contributions to Academia and Medical Training
In addition to his extensive clinical and industry experience, Nicolas Leupin is also involved in academia. He currently lectures in Tumor Biology at Universität Bern and co-founded the course 'Crosstalk between Academia and Pharma.' This course aims to bridge the gap between academic research and pharmaceutical applications, fostering collaboration and knowledge sharing in oncology research and treatment.
Scientific Advisory Involvement
Leupin served on the Scientific Advisory Board of SIRIC BRIO - Bordeaux Recherche Intégrée en Oncologie from 2018 to 2023. His role involved providing scientific guidance and advice to support research initiatives in oncology. This position highlights his commitment to advancing cancer research and his influence in shaping research directions within the field.